SOFTOX SOLUTIONS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0836 NOK | -3.69% |
|
-45.36% | -97.42% |
| Jul. 02 | Softox Solutions as Announces CFO Changes | CI |
| Jul. 02 | Softox Solutions as Announces New Board and Leadership | CI |
| Sales 2022 | 7.11M 674K | Sales 2023 | 6.98M 661K | Capitalization | 33.51M 3.17M |
|---|---|---|---|---|---|
| Net income 2022 | -71M -6.72M | Net income 2023 | -39M -3.69M | EV / Sales 2022 | 32.9 x |
| Net cash position 2022 | 6.91M 654K | Net cash position 2023 | 7.65M 725K | EV / Sales 2023 | 3.7 x |
| P/E ratio 2022 |
-3.39
x | P/E ratio 2023 |
-0.88
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on SoftOx Solutions
More press releases
| 1 day | +3.69% | ||
| 1 week | -41.18% | ||
| Current month | -41.18% | ||
| 1 month | -55.00% | ||
| 3 months | -75.00% | ||
| 6 months | -97.41% | ||
| Current year | -97.22% |
1 week
0.08
0.18
1 month
0.080.24
Current year
0.083.99
1 year
0.089.80
3 years
0.0879.70
5 years
0.08116.00
10 years
0.08116.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Geir Almås
FOU | Founder | - | 12-06-20 |
Harald Sætvedt
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olav Jarlsby
BRD | Director/Board Member | - | 15-04-16 |
Geir Almås
FOU | Founder | - | 12-06-20 |
Adrian Bignami
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 0.0836 | -3.69% | 3 276 701 |
| 24-07-04 | 0.0868 | +4.58% | 1,505,615 |
| 24-07-03 | 0.083 | -16.33% | 4,982,702 |
| 24-07-02 | 0.0992 | -39.70% | 14,550,780 |
| 24-07-01 | 0.1645 | +7.52% | 1,913,315 |
Real-time Oslo Bors, July 05, 2024 at 05:44 am EDT
More quotes
SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.
Calendar
2024-09-03
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -97.22% | 4.25M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +18.43% | 25.98B | |
| -24.33% | 19.27B | |
| -18.33% | 15.99B | |
| -17.95% | 15.66B | |
| -48.32% | 14.5B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
- Stock Market
- Equities
- SOFTX Stock
